ICMR approves SHetA2, a potential breakthrough for cervical cancer treatment
The ICMR has granted a license for the anti-cancer agent SHetA2, representing a major move toward creating a novel therapy for cervical cancer in its initial stages. According to researchers, the treatment has delivered positive results in preclinical testing. It shows promise in attacking cancerous cells while sparing healthy tissue, though additional clinical trials must be conducted before it can be used broadly.
by shortkt.com✓